NSE: ALKEM | BSE: 539523

Mid-range Performer

Download real time

5202.50 58.00 (1.13%)

26,305 NSE+BSE Volume

NSE 24 Mar, 2026 10:32 AM (IST)

62,203.7

Market Cap

High in industry

Beta 1Year

Very Low volatility

Regulatory Approval

Alkem gets DCGI nod for semaglutide; prices pens ~85% cheaper than foreign peers at Rs 1,800/month See details

Alkem Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ALKEM, BSE:539523 Alkem Laboratories Ltd.

Search Inside the pdf :

Alkem Laboratories Ltd.

18 Feb 2026

5202.50

1.13%

Expanding scope of business in the Medtech segment

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

Alkem Lab (ALKEM) is advancing its MedTech strategy through the acquisition of up to a 55% stake in Occlutech for ~EUR99m (~INR10.6b), gaining control of a specialist in minimally invasive devices for congenital heart disease, stroke prevention, and heart failure.

Alkem Laboratories Ltd. is trading below all available SMAs

Alkem Laboratories Ltd.

15 Feb 2026

5202.50

1.13%

Alkem Labs (HOLD): Ex - US international segment performing strongly

Hold: Alkem Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/APAT reported 1.3%/2.4% and -3.4% below our estimates. EBITDA margin reported 25bps lower than estimates at 22.2%

Alkem Laboratories L.. has an average target of 5995.67 from 3 brokers.

Alkem Laboratories Ltd.

15 Feb 2026

5202.50

1.13%

Temporary pause in India; new venture scale-up on cards

Buy: Alkem Laboratories Ltd.

Target

ICICI Securities Limited

Alkem Laboratories (Alkem) reported decent numbers in Q3FY26 led by its international operations. Domestic biz growth slowed to 5.6% YoY, hit by inventory stocking last year and deceleration in trade generics. Management is confident of posting double-digit growth in FY26 (9MFY26 growth at ~10%).

Alkem Laboratories L.. has an average target of 5995.67 from 3 brokers.

Alkem Laboratories Ltd.

14 Feb 2026

5202.50

1.13%

Acquisition of Occlutech to open opportunities in Med-tech segment

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

ALKEM is taking significant steps in its Medtech journey through acquiring Occlutech (develops, manufactures, and commercialized medical devices for congenital heart disease, stroke prevention and heart failure).

Alkem Laboratories L.. has an average target of 5995.67 from 3 brokers.

Alkem Laboratories Ltd.

14 Nov 2025

5202.50

1.13%

Alkem Labs (HOLD): Earnings Beat; increased EBITDA margin guidance

Hold: Alkem Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT reported 9%/9% and 2.8% above our estimates. EBITDA margin reported in line with our estimates at 23%

Alkem Laboratories L.. has an average target of 5995.67 from 3 brokers.

Alkem Laboratories Ltd.

14 Nov 2025

5202.50

1.13%

Traction across segments scaling margins to newer highs

Buy: Alkem Laboratories Ltd.

Target

ICICI Securities Limited

Alkem Laboratories (Alkem) delivered a strong Q2FY26 result led by traction across regions. Growth in India biz (+12% YoY) was led by better traction in chronic therapies and recent foray in medical devices segment, while new launches including gEntresto boosted US revenue (+28%).

Number of FII/FPI investors increased from 589 to 613 in Dec 2025 qtr.

Alkem Laboratories Ltd.

13 Nov 2025

5202.50

1.13%

Opex from CDMO/Med-tech to constrain margin expansion over the near term

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

ALKEM Laboratories (ALKEM) delivered better-than-expected revenue/EBITDA/PAT, with a beat of 6%/9%/13% for the quarter. The superior performance was driven by broad-based higher revenue growth and lower-than-expected R&D spend for the quarter.

Alkem Laboratories Ltd. is trading below all available SMAs

Alkem Laboratories Ltd.

19 Sep 2025

5202.50

1.13%

CXO 1x1: Dr. Vikas Gupta, CEO

Buy: Alkem Laboratories Ltd.

Target

ICICI Securities Limited

Alkem Laboratories’ CEO, Dr. Vikas Gupta, is targeting double-digit revenue growth in the medium term, driven by strong hold in India (68% of sales), other international markets and new ventures.

Number of FII/FPI investors increased from 589 to 613 in Dec 2025 qtr.

Alkem Laboratories Ltd.

13 Aug 2025

5202.50

1.13%

Alkem Labs (HOLD): Earnings above expectations, valuations attractive

Hold: Alkem Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT surpassed our estimates by 4%27%/46%. This was due to lower other expenses & lower ETR

Number of FII/FPI investors increased from 589 to 613 in Dec 2025 qtr.

Alkem Laboratories Ltd.

13 Aug 2025

5202.50

1.13%

Strong show; growth outlook improving

Buy: Alkem Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

Alkem Laboratories (Alkem)’s Q1FY26 performance exceeded our expectations on all fronts. The outperformance was led by a strong showing in India (up 12%) and improved momentum across US (+8.8%) and other international markets (+9%).

Alkem Laboratories L.. has an average target of 5995.67 from 3 brokers.

Is Alkem Laboratories Ltd. worth buying?

141 Votes:

Buy 79.43%

Sell 14.18%

Hold 6.38%

RESEARCH REPORTS

Neutral SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf